- Home
- DSGN vs AVTX Comparison
DSGN vs AVTX Comparison
Compare DSGN & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- AVTX
- Stock Information
- Founded
- DSGN 2017
- AVTX 2011
- Country
- DSGN United States
- AVTX United States
- Employees
- DSGN N/A
- AVTX N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- AVTX Health Care
- Exchange
- DSGN Nasdaq
- AVTX Nasdaq
- Market Cap
- DSGN 208.9M
- AVTX 248.3M
- IPO Year
- DSGN 2021
- AVTX 2015
- Fundamental
- Price
- DSGN $5.74
- AVTX $15.35
- Analyst Decision
- DSGN
- AVTX Strong Buy
- Analyst Count
- DSGN 0
- AVTX 9
- Target Price
- DSGN N/A
- AVTX $30.14
- AVG Volume (30 Days)
- DSGN 201.9K
- AVTX 450.4K
- Earning Date
- DSGN 11-06-2025
- AVTX 11-06-2025
- Dividend Yield
- DSGN N/A
- AVTX N/A
- EPS Growth
- DSGN N/A
- AVTX N/A
- EPS
- DSGN N/A
- AVTX N/A
- Revenue
- DSGN N/A
- AVTX $441,000.00
- Revenue This Year
- DSGN N/A
- AVTX N/A
- Revenue Next Year
- DSGN N/A
- AVTX N/A
- P/E Ratio
- DSGN N/A
- AVTX N/A
- Revenue Growth
- DSGN N/A
- AVTX N/A
- 52 Week Low
- DSGN $2.60
- AVTX $3.39
- 52 Week High
- DSGN $7.77
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- DSGN 43.44
- AVTX 68.66
- Support Level
- DSGN $6.01
- AVTX $13.21
- Resistance Level
- DSGN $7.21
- AVTX $15.99
- Average True Range (ATR)
- DSGN 0.62
- AVTX 1.21
- MACD
- DSGN -0.12
- AVTX 0.02
- Stochastic Oscillator
- DSGN 3.65
- AVTX 81.99
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).